Assessment of CR6261, a Monoclonal Antibody Against the Influenza A Virus

NCT01406418 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza

Interventions

BIOLOGICAL: CR6261 2 mg/kg
BIOLOGICAL: CR6261 5 mg/kg
BIOLOGICAL: CR6261 15 mg/kg
BIOLOGICAL: CR6261 30 mg/kg
BIOLOGICAL: CR6261 50 mg/kg
BIOLOGICAL: Placebo

Sponsor

Crucell Holland BV

Collaborators

[object Object]